Cyclopentolate Hydrochloride
Generic: CYCLOPENTOLATE HYDROCHLORIDE
Basic Information
Manufacturer
Bausch & Lomb Incorporated
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
OPHTHALMIC
FDA Set ID
ad85b220-6003-4a78-b900-5195ceaf0fd5
Indications & Usage
INDICATIONS AND USAGE Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.
Warnings
WARNINGS FOR TOPICAL OPHTHALMIC USE.
NOT FOR INJECTION.
This preparation may cause Central Nervous System (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger cyclopentolate hydrochloride solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
To minimize absorption, use only 1 drop of a 1% cyclopentolate solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes.
Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
NOT FOR INJECTION.
This preparation may cause Central Nervous System (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger cyclopentolate hydrochloride solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
To minimize absorption, use only 1 drop of a 1% cyclopentolate solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes.
Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
Adverse Reactions
ADVERSE REACTIONS Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported.
Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people.
This drug produces reactions similar to those of other anticholinergic drugs, but the CNS manifestations as noted above are more common.
Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, necrotizing enterocolitis (in preterm infants), unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people.
This drug produces reactions similar to those of other anticholinergic drugs, but the CNS manifestations as noted above are more common.
Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, necrotizing enterocolitis (in preterm infants), unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .